Mauna Kea Technologies

Share Issue/Capital Change • Mar 31, 2014

PARIS, March 31, 2014 – Mauna Kea Technologies (Euronext: MKEA, FR0010609263), leader in the optical biopsy market, today confirmed that it is eligible for the new PEA-PME SME equity savings plan.

This eligibility is compliant with Decree n° 2014‐283 issued on March 4, 2014 relating to the application of article 70 of the 2014 finance law n° 2013‐1278 of December 29, 2013 defining the criteria for companies to be eligible for "PEA‐PME" SME equity savings plans:

• a workforce of less than 5,000 staff;
• annual revenue of less than €1,500m or a balance sheet of less than €2,000m.

As Mauna Kea Technologies meets the above criteria, investors can include the Company's shares in PEA-PME savings accounts, a new setup devoted to investments in smallcaps and midcaps:

• its ceiling is set at €75,000, and the terms and conditions for opening this new savings account are identical to those applicable to the equity savings plan;
• individuals can have their PEA-PME savings account in another financial establishment to the one where they have a traditional PEA equity savings plan;
• it enjoys the same fiscal advantages as the traditional equity savings plan.

About Mauna Kea Technologies

.

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use during digestive and pulmonary endoscopy procedures, including pancreatic and biliary endoscopic explorations as well as fine needle aspiration procedures. Mauna Kea Technologies also obtained CE mark for a complete range of probes dedicated to urology.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies Eric Cohen Vice President Finance Tel: +33 (0) 1 70 08 09 70 investor-vpf@maunakeatech.com

Westwicke Partners Investor Relations US Mark Klausner Tel: 443 213 0501 mark.klausner@westwicke.com NewCap. Investor Relations Europe Florent Alba Tel: +33 (0) 1 44 71 94 94 maunakea@newcap.fr